Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2022 | IDH inhibitors and the evolving AML treatment paradigm

Stéphane de Botton • 5 Jun 2022
ASCO 2022
Acute Myeloid Leukemia Leukemia

Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, reflects on the evolving treatment paradigm of acute myeloid leukemia (AML), highlighting the role of IDH inhibitors in various populations of AML. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Stéphane de Botton

Updates on established therapies in AML
19:03
Updates on established therapies in AML
Stéphane de Botton • 20 Sep 2025
A Phase II study evaluating the safety and efficacy of olutasidenib in patients with R/R mIDH1 AML
3:52
A Phase II study evaluating the safety and efficacy of olutasidenib in patients with R/R mIDH1 AML
Stéphane de Botton • 28 Nov 2022
The efficacy and toxicity of reduced venetoclax exposure in patients with treatment-naïve AML
6:53
The efficacy and toxicity of reduced venetoclax exposure in patients with treatment-naïve AML
Stéphane de Botton • 28 Nov 2022
Treatment strategies for patients with AML who possess a FLT3 mutation
2:15
Treatment strategies for patients with AML who possess a FLT3 mutation
Stéphane de Botton • 28 Nov 2022

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Stéphane de Botton • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Stéphane de Botton • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Stéphane de Botton • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Stéphane de Botton • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals